Last reviewed · How we verify
Placebo: Olive oil
Olive oil serves as an inert control substance with no active pharmacological mechanism.
At a glance
| Generic name | Placebo: Olive oil |
|---|---|
| Sponsor | Mario Negri Institute for Pharmacological Research |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Olive oil is used as a placebo comparator in clinical trials to establish baseline efficacy and safety profiles against an inactive vehicle. It has no known molecular targets or therapeutic mechanism of action, functioning purely as a control arm to assess the true effect of an investigational drug.
Approved indications
Common side effects
Key clinical trials
- Effect of the Consumption of Cookies Enriched With Plant Proteins and of a Vitamin D Supplement on the Progression of Sarcopenia in the Elderly (NA)
- Natural Product System and Lifestyle Modification (NA)
- Omega-3 Fatty Acids, Neuroendocrine and Attention Deficit Hyperactivity Disorder (OMNeADHD) (NA)
- Omega-3, Inflammation in ADHD With AI (NA)
- A Clinical Trial to Examine Lysoveta on Cognitive Function in Healthy Adults With Self-perceived Memory Problems (NA)
- Effect of Omega-3 Fatty Acid Supplementation on Dry-AMD Progression (NA)
- B-vitamins and Omega-3 Fatty Acids and Biomarkers of Brain Atrophy. (NA)
- Optimizing CNS DHA Delivery in Elderly Adults at Risk for Dementia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo: Olive oil CI brief — competitive landscape report
- Placebo: Olive oil updates RSS · CI watch RSS
- Mario Negri Institute for Pharmacological Research portfolio CI